摘要
Ferumoxytol, an iron replacement product in clinic practices, is an agent of superparamagnetic iron oxide nanoparticles coated with polyglucose sorbitol carboxymethylether. It is approved for the intravenous therapy of iron deficiency anemia in patients with chronic kidney disease.
Ferumoxytol,an iron replacement product in clinic practices,is an agent of superparamagnetic iron oxide nanoparticles coated with polyglucose sorbitol carboxymethylether.It is approved for the intravenous therapy of iron deficiency anemia in patients with chronic kidney disease.Compared with oral iron therapy which is poorly tolerated in many patients with gastrointestinal disorders,ferumoxytol has been considered as an efficacious and well-tolerated option for these patients[1].Besides of
作者
Jinxia Li
Feng Zhao
Chunying Chen
Jinxia Li;Feng Zhao;Chunying Chen(CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences;CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology)
基金
supported by the National Natural Science Foundation of China (21301176)
